Platelet Sensitivity to Prostacyclin and Thromboxane Production in Hyperlipidemic Patients

Summary

In 13 type II hyperlipidemics (10 males and 3 females; mean age 50.2 ± 10.6 years), in 10 type IV hyperlipidemics (7 males and 3 females; mean age 51 ± 13.3 years) and in 23 healthy age-and sex-matched controls, the following parameters were measured: plasma cholesterol; plasma TG; plasma C-HDL; VLDL, separated in a preparative ultracentrifuge; C-LDL; Apo B, with immunoelectrophoretic method; platelet sensitivity to prostacyclin; TXB₂ formation in PRP; TXB₂ in serum.

This study provides evidence for: 1. Reduced platelet sensitivity to prostacyclin, more evident in type II hyperlipidemia that provides an additional mechanism involved in increased platelet aggregation found in type II hyperlipidemia.

2. Enhanced TXB₂ formation in PRP after thrombin stimulation (664.65 ± 142.18 pmol/10⁸ platelets) only in type II hyperlipidemics and such enhanced formation was positively correlated to C-LDL (r = 0.53; p <0.05) and to Apo B (r = 0.62; p <0.05); serum TXB₂ formation rate was also increased in type II hyperlipidemia.

Keywords

Hyperlipidemia - Thromboxane - Platelet sensitivity to prostacyclin

• References

• 1 Bizios R, Wong LK, Vaillancourt R, Lees RS, Carvalho AC. Platelet prostaglandin endoperoxides formation in hyperlipidemias. Thromb Haemostas 1977; 38: 228 (Abstr.)
• 2 Tremoli E, Folco G, Agradi E, Galli C. Platelet thromboxanes and serum cholesterol. Lancet 1979; 1: 107-108
• 3 Stuart MJ, Gerrard JM, White JG. Effect of cholesterol on production of thromboxane B₂ by platelets in vitro. N Engl J Med 1980; 302: 6-10
• 4 Shattil SJ, Bennet JS, Colman RW, Cooper RA. Abnormalities of cholesterol phospholipid composition in platelets and low-density lipoproteins of human hyperbetalipoproteinemia. J Lab Clin Med 1977; 89: 341-353
• 5 Zahavi J, Betteridge JD, Jones NAG, Galton DJ, Kakkar VV. Enhanced in vivo platelet release reaction and malondialdehyde formation in patients with hyperlipidemia. Am J Med 1981; 70: 59-64
• 6 Patrono C, Ciabattoni G, Pinca E, Pugliese F, Castrucci G, De Salvo A, Satta MA. Low dose aspirin and inhibition of thromboxane B₂ production in healthy subjects. Thromb Res 1980; 17: 317-327
• 7 Bom GVR. Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature 1962; 194: 927-929
• 8 Mehta P, Mehta J. Platelet function studies in coronary heart disease: VIII. Decreased platelet sensitivity to prostacyclin in patients with myocardial ischaemia. Thromb Res 1980; 18: 273-277
• 9 Lewy RJ, Smith JB, Silver MJ, Saia J, Walinski P, Weiner L. Detection of thromboxane B₂ in peripheral blood of patients with Prinzmetal angina. Prostaglandins Med 1979; 42: 425-431
• 10 Roschlau P, Berut E, Gruber W. Enzymatische Bestimmung des Gesamt-Cholesterins in Serum. Z Klin Chem Klin Biochem 1974; 12: 226-231
• 11 Wahlefeld AW, Bergmeyer HU. Methoden der enzymatischen Analyse. 3.. Band II, Verlag Chemie Weinheim: 1974: 1878-1886
• 12 Lopes-Virella MF, Stone P, Ellis S, Colwell JA. Cholesterol determination in high density lipoproteins separated by three different methods. Clin Chem 1977; 23: 882-888
• 13 Havel RJ, Eder HA, Bragdon JH. The distribution and chemical composition of ultracentrifugal separated lipoproteins in human serum. J Clin Invest 1955; 34: 1345-1353
• 14 Laurell S. Plasma free fatty acids in diabetic acidosis and starvation. Scand J Clin Invest 1956; 8: 81-82
• 15 Kannel WB, Castelli WB, McNamara PM. The coronary profile: 12 year follow-up in the Framingham study. J Occup Med 1967; 9: 611-619
• 16 Kannel WB, Castelli WB, Gordon T, McNamara PM. Serum cholesterol, lipoproteins and the risk of coronary heart disease. The Framingham Study. Ann Intern Med 1971; 74: 1-12
• 17 Shattil SJ, Ahaya-Galindo R, Bennet J, Colman RW, Cooper RA. Platelet hypersensitivity induced by cholesterol incorporation. J Clin Invest 1975; 55: 115-126
• 18 Carvalho ACA, Lees RS. Platelets, intravascular coagulation and fibrinolysis in hyperlipidaemias: relationship to thromboembolic complications. Acta Med Scand (Suppl) 1980; 642: 101-112
• 19 Wörner P, Patscheke H. Hyperreactivity by an enhancement of the arachidonate pathway of platelets treated with cholesterol-rich phospholipid-dispersions. Thromb Res 1980; 18: 439-451